Pharma Companies Stick To Their Roots In India As 40 Percent Yearly Growth Is In Sight
MUMBAI - Dusty roads, poor sanitation, rickety primary health centers, low income levels and sparse availability of qualified doctors - hardly a compelling environment for large pharmaceutical companies to grow their businesses but a few are bracing up to the challenges of the great Indian rural market
More from Archive
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
More from Scrip
Roche believes it can ride out any short-term effects of US tariffs if they are imposed but wants to see reform of US and European pricing to help support the sector.
In its first pharma collaboration, Tessellate Bio has inked a deal potentially worth more than €500m with Boehringer Ingelheim for therapies for ALT tumors.
Japanese CDMO Bushu talks about a consortium designed to provide a broad range of development services to smaller foreign firms looking to bring high-need drugs to the Japanese market.